This inventor holds 2 USPTO granted patents and 3 published patent applications and 1 EPO patent. Top assignee: Life Technologies Corporation. Active years: 2011-2012.
Company Filing History:
Years Active: 2011-2012
Title: Thomas Livelli: Innovator in Cardiotoxicity Screening
Introduction
Thomas Livelli is a notable inventor based in Madison, WI (US). He has made significant contributions to the field of cardiotoxicity screening through his innovative patents. With a total of 2 patents, Livelli's work focuses on improving the safety and efficacy of drug development.
Latest Patents
One of Livelli's latest patents is the "Fluorescence polarization hERG assay." This invention discloses assays, methods, and kits for screening test compounds for their capability to induce cardiotoxicity in a subject. Specifically, it assesses whether a test compound prolongs the Q-T interval as measured by an electrocardiogram in humans. The assays utilize the binding interaction between novel fluorescent tracers and the hERG K-channel, highlighting the propensity of a test compound to influence that binding interaction.
Another significant patent is the "Method for using division arrested cells in screening assays." This method employs division arrested cells to determine the effect of a substance of interest on the cells. These cells are particularly useful in drug screening assays, signal transduction assays, and large-scale, high-throughput assays.
Career Highlights
Thomas Livelli is currently associated with Life Technologies Corporation, where he continues to advance his research and innovations. His work has been instrumental in enhancing the methodologies used in drug safety assessments.
Collaborations
Livelli has collaborated with notable colleagues, including Zhong Zhong and David Piper, contributing to a dynamic research environment that fosters innovation.
Conclusion
Thomas Livelli's contributions to the field of cardiotoxicity screening through his patents reflect his commitment to improving drug safety. His innovative approaches are paving the way for more effective drug development processes.